Market Overview

UPDATE: Oppenheimer Reiterates Mindray Medical at Outperform and raises PT to $45 on Prosperous 4Q12 Revenue Growth

Related MR
Earnings Scheduled For August 10, 2015
Mindray Medical to Acquire the Remaining Stake in Wuhan Dragonbio

Oppenheimer published a report that reiterated Mindray Medical (NYSE: MR) with an Outperform rating and raised the price target from $39 to $45.

Oppenheimer reported that, “West Europe's 4Q 30% growth is impressive and validates our thesis that austerity favors MR. Margin stability and significant cash flow improvement are both encouraging. We expect 2013 to be another high growth year and believe the stock deserves a higher multiple now that it showed margin stability. Therefore, we raise our PT from $39 to $45.”

Mindray Medical shares closed at $37.70 on Tuesday.

Latest Ratings for MR

Jun 2015JMP SecuritiesUpgradesUnderperformMarket Perform
Mar 2015Credit SuisseDowngradesNeutralUnderperform
Mar 2015JMP SecuritiesMaintainsMarket Underperform

View More Analyst Ratings for MR
View the Latest Analyst Ratings

Posted-In: OppenheimerAnalyst Color Price Target Analyst Ratings


Related Articles (MR)

View Comments and Join the Discussion!

Get Benzinga's Newsletters